NCT07124468View on ClinicalTrials.gov

Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 13, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Infections
Interventions
DRUG

Meropenem-Pralubactam

The study is designed to enroll approximately 16 healthy participants. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Meropenem-Pralubactam

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT07124468 - Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants | Biotech Hunter | Biotech Hunter